text:
Wow... really had to work at this again this month. Fortunately I just got the Oct 15th -Nov 14th Legacy Club Downloads and couldn't resist making a photoless page using Baby Boo kit.
Here are my Lottery Numbers:
1 Spider in web
2 Pumpkins
7 Papers
8 Creatures
10 Words
16 Bats
ETA: Debra moved my page to Legacy Club Gallery instead of Miscellaneous Gallery ... broke the link so had to repost the image here again.


text:
I am so very, very sorry about your sister's death.
I wish I had solid answers for you, mothers do die of preeclampsia/eclampsia/HELLP today, even in the US, even when they have no risk factors like PCOS or obesity. We don't know exactly how many, but it is too many. Preeclampsia is sometimes slow-moving - the average time from diagnosis to delivery is two weeks, but that average encompasses women who stay relatively stable for weeks or months, and women on the other end of the spectrum who are delivered right away at term - or who get deathly sick in hours. We've had women on our boards who were "fine" at a noon appointment and in full organ failure at 2am that night. We've had women who didn't seem very sick until after they had their babies, and then died postpartum. I am so very sorry that your sister got sick so quickly and died so tragically.
Please let us know any other questions you have, or ask us to keep explaining. Wrapping our minds around this disease is hard in the best of circumstances.

subset: commoncrawl


text:
Craig Scott Capital, a registered broker-dealer located in Uniondale, NY, announced that Nicholas Scotto has joined the firm as a Registered Sales Representative.
About Craig Scott Capital, LLC
Craig Scott Capital is a registered broker-dealer dedicated to the brokerage and investment needs of its clients. The firm specializes in providing clients with strategic investment ideas in both the public markets and alternative investments. The firm delivers a high level of service, principled professionalism and the desire to fully commit to helping clients achieve their investment goals.
Craig Scott Capital is a member of the Financial Industry Regulatory Authority (" FINRA") NASDAQ and the Securities Investor Protection Corporation (" SIPC")


text:
JetKonnect our new service brand replaces JetLite effective March 25, 2012.
JetKonnect flies to 54 cities within India with over 430 daily flights with a mix of Boeing and ATR aircraft. With convenient schedules, reliable services and the option of flying Première on select routes, we are committed to make air travel a seamless experience and deliver the best value at all times.
Guests flying our Première service available on select routes enjoy our full meal service identical to our full service product on Jet Airways in all aspects including seats, seat pitch, food and beverage, on-ground offerings such as special check-in counters, lounge access etc. Economy cabin guests have the option to buy meals on board through the SkyCafé service.
Welcome aboard – and stay Konnected.
© Jet Airways (India) Ltd.


text:
Study Suggests New Options for Follicular Lymphoma
Treatment with a radiolabeled monoclonal antibody appears to be highly effective as consolidation after first-line therapy in patients with indolent, advanced-stage follicular lymphoma, according to results of a large phase III clinical trial published October 14 in the Journal of Clinical Oncology (JCO).
The results showed that consolidation therapy - a form of adjuvant therapy after initial or "induction" therapy to induce remission - with a single dose of yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin) significantly improved progression-free survival in all patient subgroups compared to patients in the control arm, who received induction therapy but not consolidation therapy. 90Y-ibritumomab is a monoclonal antibody with a radioactive isotope attached to it.
The improvement in progression-free survival held up regardless of whether patients had a complete response (CR) or partial response (PR) to induction therapy: 53.9 months vs. 29.5 months for CR and 29.3 months vs. 6.2 months for PR. In addition, the multinational research team, led by investigators at the Universitair Medisch Centrum Utrecht in the Netherlands, reported 77 percent of patients in the treatment arm with a PR to induction therapy "converted" to a CR after receiving 90Y-ibritumomab. Read more
Gene Signature May Predict Recurrence of Liver Cancer
Researchers have enhanced a genetic technique for studying chemically preserved tissue samples and used it to discover a gene signature that may identify patients with liver cancer who are at risk of a recurrence. Their findings also suggest that some late recurrences (more than 2 years after the initial disease) may not be recurrences at all, but rather new primary tumors that develop in a liver damaged by environmental factors such as infection by a hepatitis virus or cirrhosis.
In the study, published online October 15 in the New England Journal of Medicine (NEJM), Dr. Todd Golub of the Dana-Farber Cancer Institute and his colleagues first overcame a technical challenge. Genome-wide expression profiling studies, which are large-scale surveys of gene activity in cells, have led to new classifications of cancers and diagnostic tools, but they can only be performed on frozen samples. Vast stores of patient samples, including specimens with long-term clinical follow-up, have been preserved with the chemical formalin rather than by freezing, and therefore are unavailable for genomic analyses. Read more
Study Suggests New Options for Follicular Lymphoma
Treatment with a radiolabeled monoclonal antibody appears to be highly effective as consolidation after first-line therapy in patients with indolent, advanced-stage follicular lymphoma, according to results of a large phase III clinical trial published October 14 in the Journal of Clinical Oncology (JCO).
The results showed that consolidation therapy - a form of adjuvant therapy after initial or "induction" therapy to induce remission - with a single dose of yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin) significantly improved progression-free survival in all patient subgroups compared to patients in the control arm, who received induction therapy but not consolidation therapy. 90Y-ibritumomab is a monoclonal antibody with a radioactive isotope attached to it.
The improvement in progression-free survival held up regardless of whether patients had a complete response (CR) or partial response (PR) to induction therapy: 53.9 months vs. 29.5 months for CR and 29.3 months vs. 6.2 months for PR. In addition, the multinational research team, led by investigators at the Universitair Medisch Centrum Utrecht in the Netherlands, reported 77 percent of patients in the treatment arm with a PR to induction therapy "converted" to a CR after receiving 90Y-ibritumomab.
"This constitutes one of the highest PR-to-CR conversion rates reported in published phase III randomized studies in first-line follicular lymphoma," they wrote. Considering the efficacy and modest toxicity associated with 90Y-ibritumomab in the trial, consolidation therapy with this monoclonal antibody "may be considered as part of the current treatment algorithm of follicular lymphoma," they concluded.
Seattle-based Cell Therapeutics, Inc., which manufactures 90Y-ibritumomab, is now seeking FDA approval to begin marketing the drug for first-line consolidation therapy in patients with follicular lymphoma, a type of non-Hodgkin lymphoma. 90Y-ibritumomab is already approved in the United States to treat follicular lymphoma that has recurred or is unresponsive to available treatment regimens.
The Firstline Indolent Trial included 414 patients from 77 medical centers across Europe. Patients received a variety of induction therapy regimens, which included different chemotherapy agents and, in approximately 15 percent of patients, also included the monoclonal antibody rituximab (Rituxan). After induction therapy, patients were randomized to no consolidation therapy or consolidation with a two-course "priming" dose of rituximab followed by a single dose of 90Y-ibritumomab. Because of the limited follow-up, there are no data from the trial yet on overall survival.
Given the positive results seen even in patients who received less aggressive induction regimens, the authors added, 90Y-ibritumomab "has the potential to maximize tumor response without using aggressive induction regimens and may reduce the need for aggressive chemotherapy."
The limited use of rituximab as part of induction therapy in the trial hinders the interpretation of its results, Dr. Oliver W. Press, chair for lymphoma research at Fred Hutchinson Cancer Research Center, cautioned in an accompanying editorial in JCO. While calling the trial a "landmark study," he noted that, based on results from several phase III clinical trials, combining rituximab "with each cycle of induction chemotherapy has become a worldwide standard."
Even so, says Dr. John Leonard, director of the Center for Lymphoma and Myeloma at Weill Cornell Medical College in New York, its good safety profile and the fact that it is well tolerated by patients makes 90Y-ibritumomab "particularly attractive for [use in] older patients," who may not handle more toxic chemotherapy regimens very well.
Radioimmunotherapy, as the use of radiolabeled monoclonal antibodies is often called, has not been widely adopted, Dr. Leonard notes, in part because it's not as easy for oncologists to use as other available treatments, including rituximab. For one thing, it has to be administered in a facility specially equipped to handle radioactive compounds.
A number of trials, Dr. Leonard continues, are ongoing that should help to clarify the role of radioimmunotherapy in patients with newly diagnosed, advanced follicular lymphoma.
—Carmen Phillips
Gene Signature May Predict Recurrence of Liver Cancer
Researchers have enhanced a genetic technique for studying chemically preserved tissue samples and used it to discover a gene signature that may identify patients with liver cancer who are at risk of a recurrence. Their findings also suggest that some late recurrences (more than 2 years after the initial disease) may not be recurrences at all, but rather new primary tumors that develop in a liver damaged by environmental factors such as infection by a hepatitis virus or cirrhosis.
In the study, published online October 15 in the New England Journal of Medicine (NEJM), Dr. Todd Golub of the Dana-Farber Cancer Institute and his colleagues first overcame a technical challenge. Genome-wide expression profiling studies, which are large-scale surveys of gene activity in cells, have led to new classifications of cancers and diagnostic tools, but they can only be performed on frozen samples. Vast stores of patient samples, including specimens with long-term clinical follow-up, have been preserved with the chemical formalin rather than by freezing, and therefore are unavailable for genomic analyses.
To address this problem, scientists at Illumina, Inc., recently developed a technique for profiling several hundred genes in formalin-fixed samples. In this study, Dr. Golub and his colleagues modified the technique to profile approximately 6,000 genes. They obtained useful information from 90 percent of the 2,000 patient samples they examined, including some collected 24 years ago.
Next, the researchers profiled liver tumors, but failed to detect a survival signature. They then hypothesized that tissues surrounding the liver tumor - rather that the tumor itself - might harbor a genetic signature associated with recurrence. This adjacent tissue is frequently abnormal in patients who have experienced infection or cirrhosis.
Using a set of 106 patients, the team identified a 186-gene signature based on the activity of genes in tissues adjacent to tumors. They validated it using samples from patients in other parts of the world. If confirmed by future studies, the signature could identify at-risk patients who might benefit from intensive treatments and preventive measures.
The ability to survey the entire genome in an unbiased manner was essential, noted Dr. Golub, who also directs the cancer program at the Broad Institute. "We never would have discovered this signature if we had only been profiling several hundred genes," he said. A commerical tool is now available for genome-wide analyses of formalin-fixed samples.
One in Four Teenage Girls Receives HPV Vaccine
One in four teenage girls has begun the process of vaccination against human papillomavirus (HPV) with the three-shot series of Gardasil, according to the 2007 National Immunization Survey-Teen. In March 2007 the Advisory Committee on Immunization Practices (ACIP) recommended that all girls age 11 or 12 be routinely vaccinated with three doses of quadrivalent HPV vaccine. The new survey was the first official government report on compliance.
The vaccination series can be started as young as age 9. The ACIP also advises females aged 13 to 26 to obtain "catch-up" vaccinations, even though Gardasil is preventive, not therapeutic, and they may have already been exposed to HPV. The quadrivalent vaccine protects against HPV types 6, 11, 16, and 18, which account for up to 70 percent of cervical cancers and 90 percent of genital warts.
The 25.1 percent vaccination rate drawn from the sample group suggests that 2.5 million of the 10 million teenage girls in the United States were vaccinated. However, the survey was completed by telephone interview in 5,474 households where a teen boy or girl aged 13 to 17 lived, and results were confirmed from medical records for only 2,947 of those teens. Furthermore, the vaccination schedule calls for three shots over the course of 6 months; thus those surveyed as having received one dose of the vaccine may not complete the full, three-shot series. Finally, some structural aspects of the survey methodology and health care provider histories could make it difficult to generalize these results either to the entire population or to specific groups, such as Latina teens.
The results were published October 10 in the Morbidity and Mortality Weekly Report, as part of a report on recommended vaccinations for adolescents. It also included compliance reports for several other ACIP-recommended vaccines indicated for adolescents.
Smoking in Middle Age Decreases Quality of Life in Old Age
It is well established that smoking shortens life expectancy, but smoking in midlife also results in a poorer quality of life in old age, according to a study published October 13 in Archives of Internal Medicine.
Researchers in Finland examined the relationship between long-term cigarette smoking and health-related quality of life (HRQoL) among 1,658 men participating in the Helsinki Businessmen Study. All the men were healthy at baseline in 1974 with a mean age of 47.8 years. The health status of 1,131 (87.9 percent) of those men alive in 2000 was re-evaluated using the RAND 36-Item Health Survey, a widely used measure of HRQoL. The researchers found that participants who never smoked lived, on average, 10 years longer than heavy smokers and had the highest (i.e., best) scores on the RAND scales.
"The differences were greatest between never smokers and heavy smokers, ranging from 4 points on the scale of social functioning to 14 points on the physical functioning scale," the scientists reported. The physical component summary score showed a graded deterioration of HRQoL as the number of cigarettes smoked daily increased.
Compared with heavy smokers, never smokers "enjoyed significantly better health status in late life, which was equal to an age difference of 10 years in the general population," the researchers noted. "From a prevention point of view, our findings of the smoking/HRQoL relationship add to the view of the burden of smoking on society. The argument of better quality of life may be especially meaningful for the aging smoker but, as our results show, for the best HRQoL [smoking] should not be started at all."
More Evidence for Role of ALK in Neuroblastoma
In August 2008, researchers identified germline mutations in the anaplastic lymphoma kinase (ALK) gene in the vast majority of families with the inherited form of neuroblastoma. They also found somatic ALK mutations in 12 percent of high-risk, spontaneous (not inherited) tumor samples. An additional four studies published in the October 16 Nature have now confirmed a role of ALK in neuroblastoma.
In the first study, investigators found three different germline mutations in ALK in eight families affected by hereditary neuroblastoma, and somatic ALK mutations in 8.4 percent of samples from spontaneous tumors and 35.7 percent of neuroblastoma cell lines. In the second study, researchers found germline ALK mutations in two out of six families, and discovered that gene number alterations and gene changes in ALK in spontaneous tumors occurred mainly in two regions on the gene.
The third study also found ALK mutations in 6.1 percent of primary tumors and 33 percent of neuroblastoma cell lines. The fourth study identified five different ALK mutations in 8 percent of neuroblastoma samples; three were somatic and two were germ-line mutations.
Importantly, these mutations appear to increase the activity of the ALK protein; the studies showed that the mutant ALK protein was overexpressed and continually activated other proteins in downstream cell-signaling pathways, which can lead to aberrant cell growth and division. Inhibiting the mutant ALK genes, either with RNA interference or with targeted drugs, decreased the proliferation of neuroblastoma cells or caused cell death in all of the studies.
"Neuroblastoma is the most common childhood cancer diagnosed before the age of one, and accounts for some 15 [percent] of all cancer deaths in children," says Dr. Charis Eng from the Cleveland Clinic in an accompanying editorial. Although further studies will be needed to define how ALK might be targeted for treatment or for genetic testing in families affected by inherited neuroblastoma, she explains, "The long-awaited discovery of a major non-syndromic neuroblastoma gene is indeed a welcome advance."
Remembering a Leading Advocate for Cancer Research
Last week the country lost a true champion of biomedical research and proponent of quality medical care for every American. Former Congressman Paul G. Rogers, one of the principal leaders in the development and passage of the National Cancer Act of 1971, died on October 13. He was 87.
I can only imagine that as a young man whose formative experiences included serving in the U.S. armed forces during World War II - for which he received the Bronze Star - Congressman Rogers could not have foreseen that he would become one the most prominent and well-respected voices in support of biomedical research and health care our country has ever known.
Even as he began the first term of an illustrious 24-year career as a member of the U.S. House of Representatives, he could not have anticipated that he would be honored by organizations like the American Cancer Society, the National Osteoporosis Foundation, and the Lasker Foundation; or that he would be elected to such prestigious organizations as the Institute of Medicine; or that he would have a plaza on the NIH campus named in his honor.
But if his actions are any indication, he truly lived his public life by his own words, which are now inscribed on a plaque in the Paul G. Rogers Plaza on the NIH campus: "Without research, there is no hope."
Congressman Rogers' accomplishments are both legion and legendary. During his 8-year tenure as chair of the House Subcommittee on Health and the Environment, he ushered through the passage of the Health Manpower Training Act; National Heart, Blood Vessel, Lung, and Blood Act; Safe Drinking Water Act; and Community Health Centers Act, just to name a few. As these laws demonstrate, although Congressman Rogers believed in the power of research, he also knew that maintaining and improving public health extended well beyond the walls of the laboratory.
Congressman Rogers was committed to ensuring that research being done at government and large academic centers was translated and delivered to the communities where most people receive their care. As he recounted in the NCI Cancer Bulletin nearly 2 years ago, among the most important provisions in the National Cancer Act were those that established the Cancer Centers Program. The continued growth of that program is a testament to Congressman Rogers' foresight and wisdom as a policy maker. The launch last year of the NCI Community Cancer Centers Program pilot is, in many ways, an extension of Congressman Rogers' fundamental belief in the importance of ensuring the translation and delivery of cutting-edge cancer care to patients where they live.
Congressman Rogers was prescient about the challenges of making quality medical care, including cancer care, available to every American, regardless of race, culture, or socioeconomic status. In a 1991 interview, he talked about the need to address the growing number of Americans without health insurance or without "adequate access to the [health care] system." He also spoke about the growing burden of the escalating cost of care. Both are issues we are still trying to come to grips with today.
Indeed, in a 1979 interview, the year he left public office, he spoke of what drove his legislative efforts in health care. "I saw the potential for what could be done…and it was just not being aggressively pursued," he said. "We were not looking ahead and planning."
As a legislator, a policy maker, a mentor, and a public health leader, Congressman Rogers' efforts have had a profound impact on biomedical research and medical care in the United States. His tireless efforts, it can be safely said, have helped build infrastructure and establish policies that will ensure continued progress for years to come.
I have lost a friend and mentor. Paul was among the first to welcome me to Washington, D.C., and to my new position at NCI. He was eager to introduce me to his many friends and was always full of encouragement whenever our paths crossed. He never saw me without saying, "We have to get you more money to do your job." He understood the importance of our nation's investment in biomedical research. I will remember his gracious manner and will do my best to follow the high standards he set for all of us.
Dr. John E. Niederhuber
Research Portfolio Offers More Information, New Tools
NCI has launched a revamped version of the NCI-Funded Research Portfolio (NFRP) on Cancer.gov. The revision consolidates information that was previously available across various pages of NCI's Web site, including funding and data on NCI's intramural research program, and makes available information not previously found on Cancer.gov.
Users can search individual disease categories and specific conditions, or use a more overarching approach to search by year of funding or key words. The research project records yielded by the search include a link to the abstract that explains their methodology and goals.
Users can also select how they would like to view the output of their searches: either a detailed "coding" report that shows all of the codes NCI's expert indexers used to categorize each research project or grant, or a "budget" report that details the proportional relevance of that project to a given category and the prorated dollars to a given category. This information can be exported into an Excel spreadsheet.
The new NFRP site can be accessed from various points on Cancer.gov, including the "Research and Funding" tab along the top, or the "Science Serving People" or "Director's Corner" portals. The NFRP will continue to undergo refinements in the coming months. Users are encouraged to submit their comments to firstname.lastname@example.com.
Lung Cancer and Erlotinib: Which Patients Benefit?
One of the most promising recent developments in cancer medicine has been the dramatic responses of some patients with lung cancer to the drugs gefitinib (Iressa) and erlotinib (Tarceva). Although only about 10 percent of patients with lung cancer respond in this way, a larger group experiences prolonged survival and an improvement in symptoms. Unfortunately, the best way to identify candidates for these drugs, called EGFR tyrosine kinase inhibitors (TKIs), is not yet clear.
NCI has launched a clinical trial called MARVEL (Marker Validation of Erlotinib in Lung Cancer) that could offer guidance. The study aims to validate a candidate biomarker for response to erlotinib: extra copies of the epidermal growth factor receptor (EGFR) gene in lung tumors. Several recent studies have suggested that patients who harbor this gene "amplification" may benefit from erlotinib. The trial will also assess other candidate prognostic markers such as EGFR gene mutations.
"This study represents a unique opportunity for the prospective validation of multiple markers," said co-principal investigator Dr. Fred R. Hirsch of the University of Colorado Health Sciences Center. He and the group at the University of Colorado Cancer Center pioneered the use of fluorescence in situ hybridization (FISH) as a means of detecting EGFR amplifications in lung tumors, and the technology will be evaluated in MARVEL along with the biomarker itself.
Breast cancer tumors are routinely analyzed using FISH to identify women who are candidates for trastuzumab (Herceptin), and the technology could readily be adapted for clinical use in lung cancer.
In the randomized trial, approximately 1,200 patients with advanced non-small-cell lung cancer (NSCLC) who were treated previously will receive erlotinib or pemetrexed, a standard second-line chemotherapy drug for lung cancer. The investigators hypothesize that erlotinib will be superior in patients who are EGFR-positive as detected by FISH, while the chemotherapy will be superior in those who test EGFR-negative.
"This study has two main purposes - to define which population will benefit the most from receiving EGFR-targeted therapies, and to validate some of the tests used to measure the EGFR target," said Dr. Claudio Dansky Ullmann of NCI's Division of Cancer Treatment and Diagnosis, who, along with Dr. Janet Dancey, formerly of NCI and now at the Ontario Institute for Cancer Research, helped develop the trial.
Multiple cancers involve the activation of the EGFR gene, either through mutation or increases in the number of gene copies of EGFR. Though EGFR gene mutations are associated with strong responses to erlotinib, sometimes lasting several years, the mutations are rare in Western populations. By comparison, approximately 50 percent of NSCLCs may harbor increased EGFR gene copy number. This suggests that the change, if validated, could be broadly useful as a biomarker of response, noted Dr. Hirsch.
"Our hope is that the trial will lead to the identification of markers that will ultimately allow the selection of a specific treatment that is likely to be the most effective for individual patients," said Dr. Dancey.
Along with molecular markers, clinical characteristics such as being a female, Asian ethnicity, and smoking fewer than 100 cigarettes in a lifetime are associated with response to EGFR TKIs. Responders also tend to have lung adenocarcinomas.
The trial will also evaluate mutations in the KRAS gene as possible biomarkers. In colorectal cancer, KRAS mutations are associated with resistance to cetuximab (Erbitux), a monoclonal antibody that targets the EGFR protein, but there is insufficient evidence to draw conclusions about these mutations in lung cancer.
"We expect that this study will teach us a lot about how the different EGFR biomarkers correlate to each other," said Dr. Hirsch, "and also about their associations with clinical outcomes."
The multicenter study is NCI's first to determine prospectively whether biomarkers can help guide treatment for lung cancer. Many partners have been involved in the planning and design from the outset, including NCI cooperative groups, the Food and Drug Administration (FDA), and the Centers for Medicare and Medicaid Services.
"The MARVEL trial is unique and an important first because it is an outgrowth of specific NCI initiatives designed to advance lung cancer therapies and received broad input from the FDA, NCI cooperative groups, the biomarker industry, and the pharmaceutical industry," said Dr. Alex A. Adjei, of the Roswell Park Cancer Institute and chair of the study, in a statement.
—Edward R. Winstead
Preventing Respiratory Infections in Patients with CLL
Name of the Trial
Principal Investigators
Why This Trial Is Important
The advanced age of most people with CLL (70 percent over age 65) is also a risk factor for infection. Acute respiratory infection (ARI) is the most common infection in CLL patients. Although there are no published data on the occurrence of ARI in untreated CLL patients, these individuals appear to be more prone to infection than people of similar age with non-cancerous conditions. Recent studies suggest the average number of days with ARI during the winter season is about 8 among cancer-free individuals who are roughly the same age as CLL patients.
Two randomized, controlled trials have shown that an extract of North American Ginseng, called CVT-E002 (COLD-fX), can significantly reduce the risk of ARI in older adults. Other research suggests that the active ingredient in CVT-E002 enhances the function of certain white blood cells (macrophages and natural killer cells) that are part of the immune system.
These results led to the development of this randomized, double-blind, placebo-controlled study to test the ability of CVT-E002 to reduce ARI and the need for antibiotic treatment during the peak respiratory illness season (January through March) in people with CLL. All patients will be enrolled between November 1 and December 31, 2008. Once patients are identified and informed consent obtained, they will be randomly assigned to receive either CVT-E002 (200 mg orally twice a day) or matching placebo pills. Treatment will continue through April 30, 2009. The researchers want to see if CVT-E002 can reduce the number of days with ARI by 30 percent, as well as antibiotic use among CLL patients over a 3-month period (January 1-March 31).
For More Information
An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.
Delving Deeper into Exercise and Breast Cancer Prevention
For women concerned about breast cancer, looking over the list of known risk factors can be cause for frustration, as few of the stronger risks appear to be modifiable. But this may change as more is learned about the role of exercise in preventing breast cancer.
A growing body of research indicates that the levels of hormones produced by the body can be modified by physical activity. While a woman cannot change her age at menarche or menopause, and may not have children or breast feed - all factors which affect the levels of ovarian hormones a woman is exposed to over her lifetime - many researchers believe that she can reduce her exposure to these hormones through exercise.
Ovarian hormones including estrogen and progesterone, for example, are necessary for a woman's reproductive and overall health, but they also stimulate breast cells to proliferate, which can increase the accumulation of genetic mutations and potentially lead to tumor formation.
"Our theory is that the accumulative number of ovulatory menstrual cycles a woman experiences is predictive of her breast cancer risk," explains Dr. Leslie Bernstein, professor of cancer etiology at City of Hope Comprehensive Cancer Center.
She and her colleagues have been involved in the California Teachers Study (CTS) since 1995, which enrolled 133,479 current and retired teachers and school administrators in the state of California to prospectively study potential causes of an excess incidence of breast and other cancers observed in this population.
Last year the CTS investigators found that the risk of invasive breast cancer was inversely associated with long-term strenuous physical activity - women who averaged more than 5 hours a week of strenuous physical activity between high school and their current age (or age 54 if 55 or older) had a significantly reduced risk compared to women who averaged less than half an hour of strenuous physical activity a week during the same period of life.
Unexpectedly, neither strenuous nor moderate long-term physical activity was associated with reduced risk of estrogen receptor (ER)-positive breast cancer, but women who participated in long-term strenuous physical activity had a 55 percent reduction in risk of ER-negative breast cancer, and women who participated in long-term moderate physical activity had a 47 percent reduction in risk.
While drugs such as tamoxifen and raloxifene can help prevent the formation of ER-positive breast cancer, no such agents currently exist that can help prevent ER-negative cancer, making interventions to reduce the risk of ER-negative cancer "critically important," says Dr. Bernstein.
Investigators from NCI's Division of Cancer Epidemiology and Genetics (DCEG) recently obtained similar results from their National Institutes of Health-American Association of Retired Persons (AARP) Diet and Health Study, another prospective cohort study begun in 1995. They examined current physical activity among women aged 50 to 71 at the beginning of the study and evaluated physical activity in relation to breast cancer diagnosis according to hormone-receptor status. Their results were consistent with the CTS, showing that higher levels of exercise decreased the risk of ER-negative breast cancer.
Other studies are needed to tell "whether the apparent protective effect of physical activity on breast cancer risk observed was due to a direct effect of exercise on hormone levels," says Dr. Michael Leitzmann, formerly of DCEG and lead investigator on the study. Other factors may also affect how exercise modulates breast cancer risk, including decreased levels of circulating insulin and insulin-like growth factors, reduction of chronic inflammation, and modulation of the immune response.
In addition to questions about mechanism, it's not yet clear how much exercise is needed for a protective effect, nor at what age exercise may have the greatest benefit on breast cancer risk. However, recent data from the Nurses' Health Study II (NHSII) suggest that beginning regular exercise early in adolescence and young adulthood may be important for the prevention of premenopausal breast cancer.
Investigators from the NHSII examined lifetime physical activity beginning at age 12 in 64,777 premenopausal women, and found a 23 percent reduction in risk for premenopausal breast cancer among women who exercised, on average, an equivalent of 3.25 hours a week of running or 13 hours a week of walking during adolescence. "Long-term, sustained activity showed the greatest benefit," says Dr. Graham Colditz, professor of medicine at Washington University in St. Louis and senior author of the study.
However, high levels of physical activity during ages 12 to 22 contributed most strongly to the observed reduction in risk in the NHSII study. Researchers speculate that this may have something to do with a vulnerable period in breast development. "From the time of early onset of puberty until first pregnancy, that's a time of maximal risk accumulation in terms of the breast not being fully developed, and that can be a period of great hormonal irregularity for many reasons beyond pubertal growth and maturation, including weight change, physical activity changes, dietary changes, and alcohol exposures," explains Dr. Rachel Ballard-Barbash, associate director of the Applied Research Program in NCI's Division of Cancer Control and Population Sciences.
"But most studies suggest that even if you weren't physically active at one period of life, that becoming physically active at any point in your life is beneficial," she continues. "It's just as important for women to be conscious of their overall health as it is to be conscious of things that may have a specific influence on their breast health."
—Sharon Reynolds
FDA Takes Action on Ovarian Cancer Screening Test
The Food and Drug Administration (FDA) has issued a letter to Laboratory Corporation of America (LabCorp) saying the company lacks the legal authority to market its OvaSure test for the early detection of ovarian cancer. LabCorp rolled out the test last spring, shortly after results from a phase II clinical trial suggested the test is effective at both detecting disease early and identifying women who don't have it.
In the letter to LabCorp, Dr. Steven Gutman from the FDA's Center for Devices and Radiological Health said an agency review of information about OvaSure "revealed serious regulatory problems involving these devices manufactured by your firm."
The FDA typically does not require agency clearance of tests that will only be conducted at a single, central laboratory, as is the case with OvaSure. But tests have to be developed and manufactured by a single entity to receive such an exemption. OvaSure was developed by researchers from Yale University and includes components manufactured by other companies.
LabCorp began offering the test in June, specifically for use in women at high risk for the disease "to enhance the potential of detecting and treating ovarian cancer in its early or localized stage when the likelihood of survival is greatest," LabCorp Chief Medical Officer Dr. Myla Lai-Goldman said at the time. The 5-year survival rate in women for whom the disease is caught early, which happens in approximately one in five cases, is more than 90 percent. In women diagnosed with advanced disease, it drops to 30 percent.
Even before the FDA action, some concerns were expressed in the clinical community that OvaSure may have been introduced into commercial use prematurely. In July, for example, the Society of Gynecologic Oncology issued a position statement saying that "additional research is needed to validate the test's effectiveness before offering it to women outside the context of a research study."
The test is undergoing further evaluation in a phase III clinical trial in collaboration with NCI's Early Detection Research Network.
A LabCorp spokesperson told the Wall Street Journal's health blog that the company is "committed to working in partnership with the FDA to address the regulatory issues [raised in the agency's letter] and will provide an update as soon as we can."
Breast Density in Mammography and Cancer Risk
Studies from the last 3 decades have shown that breast density is directly linked to breast cancer risk. The magnitude of that risk is still under some debate, says Dr. Stephen Taplin, a senior scientist in NCI's Division of Cancer Control and Population Sciences who leads research on breast cancer screening as the project director for the Breast Cancer Surveillance Consortium (BCSC). But, he continues, "it is widely held to be one of the biggest risk factors, though the question of why it carries such a high risk is still not answered."
Breast density is not an intuitive concept, and has little to do with breast size. Breast density actually refers to the amount of white area on a breast that otherwise appears black on a mammogram. The balance of white and black reflects the breast composition and relative amount of glandular tissue, connective tissue, and fat. Different methods of estimating the proportion of white area on the mammogram exist and vary from the perception of the radiologist to using a software program to outline the white area and compare it to the total breast area.
Though it can be influenced by lifestyle factors, twin studies show that the underlying causes of breast density are mostly inherited. Higher breast density is more common in some ethnic groups, including White women. It is also more common in younger women, beginning when hormones kick in during puberty and continuing through the childbearing years.
Breast density decreases during menopause in a process called breast involution, where the milk-glands and ducts atrophy and connective tissue disappears. But in some women, these tissues persist into older age, and these are the women for whom the risk is a real concern, says Dr. Karla Kerlikowske, a professor of medicine and epidemiology and biostatistics at the University of California, San Francisco (UCSF) and principal investigator for the San Francisco BCSC research site.
"A 30-year-old woman can have dense breasts, but her underlying risk is still likely very low without other known risk factors," she explains. "We're really concerned with women who are in their 50s and 60s, who have persistent breast density, and who may benefit from a different screening procedure or some other preventive measure, such as chemoprevention."
To identify such women, Dr. Kerlikowske and colleagues in the BCSC published breast cancer risk prediction models in the Journal of the National Cancer Institute and the Annals of Internal Medicine. These models used the most common measurement for breast density, BI-RADS, to project cancer risk out to 1 and 5 years respectively for Caucasian, Asian, Hispanic, and Black women between the ages of 40 and 74, taking into account family history and breast biopsies.
The second model correctly identified women as low-risk and high-risk slightly better than the Gail model, but in the middle-risk group it was similar to the Gail model. The model hasn't been developed for clinical use, according to their paper.
The BI-RADS measuring system involves a radiologist scoring a mammogram in one of four categories according to the extent of contrast within the outline of the breast: x-rays pass easily through fatty tissue, which shows up as darker areas on the image, but are blocked - and thus appear white - by milk ducts, lobes, and the web of connective tissue that tethers everything together. Studies have shown that women who have extremely dense breasts have a three- to fivefold increased risk of breast cancer compared with women who have mostly fatty breasts.
One concern has been whether the breast cancer associated with dense breasts is due to a "masking effect," where the lack of contrast (that is, a breast image that is very white throughout) between normal tissue and tumors in dense breasts makes it difficult to discriminate between the two.
However, this isn't the only explanation for the relationship. "If we look at the risk association over time," says Dr. Taplin, "the longer out we go, the more evident it is that there's a fundamental risk factor that isn't about masking. It's something about the tissue itself."
"Our working hypothesis is that the elevated risk associated with mammographic density reflects an altered microenvironment," explains Dr. Gierach, noting that they are looking closely at hormone levels and markers of inflammation. Another DCEG project led by Drs. Mark H. Greene and Jennifer Loud, the Breast Imaging Study, is examining how BRCA1 or BRCA2 gene mutations relate to breast density and includes a pilot analysis of the relationship between mammographic density, circulating estrogens, and estrogens within the breast itself.
Until there is an accurate and precise means to measure breast density, even though it is widely acknowledged as important in the scientific literature, it will not be a widespread consideration in the clinic, says Dr. Kerlikowske. "The reason is that we need a reliable measure in the clinic, and clinicians need to be trained to interpret risk information that includes a breast density measure."
She uses blood cholesterol and bone mineral density tests to illustrate the point. "When I order one of these tests on a woman, I get a printout that tells me what her score is, where she is in relation to women her age, and what I should do in terms of an intervention," she explains. "We need cost-effectiveness analyses to figure out the threshold for when a woman's breast cancer risk warrants clinical intervention - a different screening procedure, or chemoprevention, for example. Clinicians need to know the threshold of risk that requires an intervention."
They also need a measure of breast density that is more quantitative than the subjective BI-RADS system, she says. To this end, she and colleagues at UCSF are pilot-testing a new technology that calculates volumetric measurements of breast density using standard mammogram equipment. "That's where the future lies, and that's when you'll see breast density more widely used in the clinic," she says.
The conversation about breast density and cancer risk will principally be between researchers and clinicians until the issues surrounding density measurement and sub-groups of women who have dense breasts, and thus higher risk, get sorted out. But it isn't too early, some researchers advise, for women to discuss the matter with their doctors if they have concerns. This may be particularly important, says Dr. Taplin, for women who have persistent lumps but a negative mammogram.
—Brittany Moya del Pino
NCI Staff Elected to IOM
Membership in the IOM is considered one of the highest honors in the fields of health and medicine, and it recognizes individuals who have demonstrated outstanding professional achievements and commitment to service. Current active members elect new members from among candidates nominated for their accomplishments and contributions to the advancement of the medical sciences, health care, and public health.
Davis Named DTP Branch Chief
Before joining NCI, she worked at Eli Lilly Research Laboratories as a research advisor in toxicology in their Investigative Toxicology Group, where she focused on the development of kinase inhibitors as therapeutic agents. Prior to that, Dr. Davis was an associate professor in the Department of Pathology at the University of Maryland School of Medicine, where her research explored the mechanisms of toxin-induced apoptosis.
As branch chief of TPB, she serves as the toxicology expert for project and program teams in drug discovery through first human dose, provides mechanistic toxicology expertise, and creates and leads major research initiatives.
Understanding NCI Teleconference Series Continues
No registration is required for participation. To join the teleconference, dial toll-free 800-857-6584; the passcode is: CIS. Toll-free playback will be available through November 29 at 800-216-6079. For more information about the "Understanding NCI" teleconference series and to learn about past teleconferences, go to: http://advocacy.cancer.gov/.
Breast Cancer Program-development Guidelines for Poorer Countries
The NCI Office of International Affairs, headed by Dr. Joe Harford, is one of 19 international collaborating organizations of the BHGI, which works to advance the global fight against breast cancer.
Steven Bognar and Julia Reichert are filmmakers of the Emmy Award-winning documentary A Lion in the House, a film about the lives of five American families who each have a child battling cancer. Since its release in 2006, the film has been widely used by patient advocates and health agencies to promote greater understanding of the challenges facing pediatric patients and their families. It was recently released in a DVD edition.
What has been the response to the documentary, especially its use for education and advocacy?
The DVD is packed with bonus features, including a short film updating viewers on all of the kids and their families. The film has been used in so many educational settings, we've lost count. At the same time, health care educators in many fields have asked for shorter clips for classroom use. So our team began - with major support from the Centers for Disease Control and Prevention, the Lance Armstrong Foundation, and SuperSibs! - tocreate from the film and its outtakes a series of targeted educational modules on selected subjects, include survivorship, health care disparities, end-of-life communication, school issues, nurse boundaries, sibling issues, and spirituality issues. Each mini-movie module comes with unique learning objectives, discussion questions, competencies, take-home points, and an in-depth resource list. The educational materials can be purchased on the Web at http://www.aquariusproductions.com.
The modules have been designed with input from a team of top experts in their respective fields, who looked at draft after draft to help us refine and improve them. They are for many audiences - medical and nursing students, residents, fellows, nurses, social workers, and others.
The module on disparities has been used to advocate for transportation support for poor families, and the school issues module has been widely used to educate school nurses and counselors on childhood cancer's impact on learning, for both children with cancer and their siblings. We are extremely gratified that many organizations in our field have embraced the film and the related modules and have found creative ways to use them.
How has your involvement in making the film affected your lives and work?
What can potential filmmakers or advocates do if they are considering approaching a subject like this?


text:
The Challenge Was Issued
Scenes from PUMA's PT3 Tournament.
More power, speed, and tricks. Top players and big fans. Unreal performances and a love for the game that start at 0:01 and refuse to quit.
PUMA is on a sustainability journey to improve our business and the lives of generations to come.
Scenes from PUMA's PT3 Tournament.


text:
HPC Market Watch
|HPCwire Market Watch
1,377.93 -14.46 (-1.04%)
Streaming Delayed Price / Updated: 8:10 PM EDT, Sep 23, 2014 / Add to My Watchlist
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
September 23, 2014
- NSF and SRC Announce Nine Research Awards
- University of Delaware Deploys Second HPC Cluster
- NIBMG to Utilize DDN Storage
- University of Virginia Receives New Cluster to Enhance Research
- PRACE Launches First Phase of PCP
September 22, 2014
- RSC Group to Create Supercomputing Center for SPbSPU
- Dr. Brian Greene to Keynote SC14
- Fujitsu to Provide KAU with a New HPC System
- Bill Blake Joins D-Wave Systems
- AIBN Purchases New Supercomputer
- Racklive Introduces New Low Latency Server Line
September 19, 2014
- Intersect360 Research Releases New Report on HPC Applications
- Gordon Bell Receives Seymour Cray Computer Engineering Award
- ZIH Becomes Intel Parallel Computing Center
September 18, 2014
- Altair to Showcase Oil and Gas Simulation Technology in Houston
- Asetek to Present Latest Products at HPC for Wall Street Conference
- Satoshi Matsuoka Recognized with 2014 Sidney Fernbach Award
- Titan Supercomputer to be Utilized for Engine Knock Research
- IDC Releases New Information on Worldwide HPC Server Market
September 17, 2014
Most Read Features
- Intel âHaswellâ Xeon E5s Aimed Squarely at HPC
- Will 2015 Be the Year of the FPGA?
- Cray Adds GPU Powerhouse to CS Supercomputer Lot
- New Degrees of Parallelism, Old Programming Planes
- New Haswells Spark Open Season for HPC Systems
- A Return to Roots for New Cray CTO
- CEO of HPCâs Silent Giant Offers Outlook
- Whatâs Still Missing for HPC Users in Manufacturing
- Cray CEO Highlights Enterprise HPC Growth
- CPUs Outperform GPUs in Financial Markets Benchmark
- More Features…
Most Read Short Takes
- A New Era in HPC
- Myths and Misconceptions about HPC for Engineering
- House Bill Takes Aim at Exascale
- Google Expands Quantum Computing Program
- Europe Launches Ultrascale Computing Initiative
- Supercomputing Facilitates Breakthrough Cancer Treatment
- HPC Task Force Publishes Recommendations
- GPUs Advance Deep Learning
- The Surprising Science Behind Everyday Products
- NVIDIA Boasts âCompelling HPC Solutionâ
- More Short Takes…
Most Read Off The Wire
- HPC Wales Awarded ISO 9001 Certification
- Top Supercomputers of India List Released
- Steve Scott Rejoins Cray as Senior Vice President and CTO
- HPC 2015 Issues Call for Papers
- Next-Generation Cray Supercomputers to Include Intel Xeon Processor E5-2600 v3 Product Family
- HP to Acquire Eucalyptus
- Satoshi Matsuoka Recognized with 2014 Sidney Fernbach Award
- Seagate Announces Availability of ClusterStor 9000
- HP Unveils New ProLiant Gen9 Servers
- Fujitsu to Provide KAU with a New HPC System
- More Off The Wire…
Feature Articles
Clouderaâs Wolfgang Hoschek Talks of Hadoopâs EvolutionWolfgang Hoschek is a software engineer at Cloudera working on the Hadoop platform and Cloudera search team. He is a committed member of the Read more…
BE Matters to Robert Dunn, Saginawâs SonRobert Dunn, Jr. was born in Saginaw, Michigan, in 1985. He earned a bachelorâs degree in Computer Science (CS) from Florida Agricultural and Read more…
The Most Powerful Tool in the Climate Change BattleClimate change has been at the top of the news agenda this week, in part because of the attention around a massive public protest in New York Read more…
Short Takes
Autotune Software Promotes Greener BuildingsA new software effort underway at Oak Ridge National Laboratory (ORNL) aims to make it quicker, easier and cheaper to model energy use of Read more…
Seismic Explorers Set Exascale CourseIn a recent blog post, Cray Senior Practice Leader Geert Wenes argues that "a perfect storm in seismic processing requirements" is ensuring that Read more…
Quick Change Material Begs Post-Silicon ConsiderationWith Moore's law in peril, the search is on for the next computing substrate. Keeping up the pace of progress in an ever more compute and data Read more…
Sponsored Whitepapers
SpotlightON: Software-Defined Networking in the Datacenter9/4/14 | Extreme Networks | When it comes to networking, switches and routers are breaking free of their physical constraints to create readily reconfigurable software Read more…
SpotlightON: Scaling for Research and Analytics in the Cloud8/26/14 | Amazon Web Services | Many HPC applications are experiencing unprecedented agility in the cloud - the flexibility to scale up and out depending on workload demands and Read more…
Sponsored Multimedia
Webinar: Revolutionizing Innovation: When HPC Meets CloudLearn how real end-users are utilizing HPC cloud as a cost-effective way to manage limited resources. From building a faster bicycle to the Read more…
On Demand Webcast: Warm Water Cooling Technology for an Energy Efficient DatacenterWatch today this webcast where Cray and Mississippi State University shares best practices in choosing a cluster architecture to include  site Read more…
HPC Job Bank
Featured Events
IP EXPO EuropeOctober 8 - 9Royal Victoria Dock London United Kingdom
15th International Cloud Expo Silicon ValleyNovember 4 - 6Santa Clara CA United States
LISA'14November 9 - 14Seattle CA United States
SC14November 16 - 21


text:
You want to hit the weights.
You only have 15-20 minutes at the gym.
NO! Not by doing a few sets of these:
It's pretty simple. You pick an exercise. Find a weight that you can do 8-10 times. Then do this:
7 reps - FULL Range of Motion
7 reps - HALF Range-of-Motion (this would be the FIRST half, or 0-45 degrees)
7 reps - HALF Range-of-Motion (this would be the SECOND half or 45-90 degrees)
7 reps - FULL Range of motion.
A few things to keep in mind:
- Try to rest as LITTLE between sets as possible
- If you get through the last set of 7 and it's still not very challenging, INCREASE your weight!
- This will take 3-4 minutes. If you rest 1 minute before you get into the next exercise, you can get a serious workout in not much time at all!!


text:
That's a beautiful photo, L. I'm glad you had a good time at the party. I am so jealous of where you live!
We've got about 6 inches of snow on the ground and it's still falling. It's that teeny tiny kind that just won't stop and seems to accumulate really quickly. I had to take both boys out in it today (Cash to nursery and Travis to school). I got a text from the teacher I work with saying that our school was closed, but no such luck for the boys. The roads are horrendous. I nearly slid in to a parked car (side note-I haaaaaaaaaate how narrow the roads are here and how people don't always have driveways, so they park on both sides of the road, leaving a narrow road even narrower!) Then, I wasn't even thinking and dropped Cash off at nursery, but parked in the parking lot, which is on a hill, so I got stuck in the snow! I had to have staff come out and put some grit down and then 2 men pushed the car up the hill about 10 feet for me. I felt so embarassed; I'm sure they all thought that I was an idiot for even parking in the parking lot instead of just leaving the car on the main road, where I would have had to walk with both kids in the snow for 5 minutes to reach the building. But any how. That's done and over with now. I'll have to go back out in about an hour to pick them up, and I'm going to creep along and be hyper aware of every car around me.


text:
|Thread Tools
|Search this Thread
|Display Modes
Angel Governing Dec 3rd to 7th
Angel number 51 - ANGEL HAHASIAH - Energy: UNIVERSAL MEDICINE
(I pronounce the Angel's Name: HAHA-SEE-AH)
Qualities: Ability to understand - Favors definitive healing - Detects and understands the cause of illness - Great healer, bearer of universal 'remedies' - Bestows the philosopher's stone - Reveals essential truth leading to understanding of the dynamic of the universe - Expert in esoteric knowledge (alchemy, metaphysics) - Genuine seer, elevated soul.
Distortions: charlatan, breaks promises - swindler exploiting the ignorant - abuse of good faith - deceives others - victim of fraud - illusion - manipulator.
I would like to share with you the following.
Standing, sitting or lying down, breathe in the name HAHASIAH by inhaling through the nose, and hold your breath a few seconds. Then, exhale slowly and progressively through the nose. Repeat the exercise as long as needed to create a state of calm. Then you can continue by breathing freely while continuing to invoke HAHASIAH keeping the eyes closed.
By invoking or repeating the Sacred Formula represented by the Angel's name, we create a passage between the conscious, the subconscious and the different layers of the unconscious, thus reprogramming the different Angelic states of consciousness within, and allowing ourselves to reconnect with our celestial origin. The objective of this work is to purify our soul and become totally conscious in order to rediscover the Knowledge that lies within.
HAHASIAH is your Angel number 1 (Physical) if your Birthday is Dec 3rd to Dec 7th
HAHASIAH is your Angel number 2 (Emotional) if your Birthday is: May 11th, July 25th and 26th in the morning, Oct 8th, Dec 19th, Feb 27th.
HAHASIAH is your Angel number 3 (Intellectual) if you are born: 16h40 to 16h59 p.m.
In the picture of the Tree of Life, this Angel resides: NETZACH/ Specificity HESED
This information is taken from The Book of Angels, and Les Ailes de la Vie (Wings of Life, 2nd Edition)and Traditional Angelology and Angelica Yoga written by Kaya and Christiane Muller, Univers/Cité Mikaël. www.72angels.ca
Pema Norpal
Know Thyself and You Will Know The Universe
« Previous Thread | Next Thread »
|Thread Tools
|Search this Thread
|Display Modes
Hybrid Mode
All times are GMT -7. The time now is 07:11 AM.


text:
Hot Pink Roses Red Parasol OOAK Ivory Trim Steampunk Lolita
Contact Seller
Color: Pink
Fast, Easy, Secure Checkout.No Account Required
dbvictoria last checked in:
You are viewing this page with IE7 (or in Compatibility Mode). IE7 is no longer supported, please remove compatibility mode or use a newer browser.
We recommend the following:


text:
By Sydney Bucksbaum, Hollywood.com Staff
He's basically the greatest specimen ever to walk this earth. He's beautiful, he's sexy, he's talented, he's a good person, and he's every woman's dream. Men want to be him. Dogs want to be owned by him. But not everyone can attain the perfection that is Ryan Gosling.
In honor of his movie, Gangster Squad, which opened in theaters Friday, we've compiled a gallery filled with photos of Ryan Gosling Doing Things. But we did you one better: we modified that gallery to Ryan Gosling Doing Things In Tank Tops. Yeah, you're welcome.
Although, we really should be thanking Gosling himself for letting those giant, bulging guns air out all the time. Tank tops have never looked so good.
And so, without further ado, we present to you:
Gratuitous Gosling Gallery: Tank Tops Edition
[Photo Credit: Splash News]
Follow Sydney on Twitter @SydneyBucksbaum
Lindsay Lohan: 'New York Times' Piece Is the Best Thing That's Happened to Her in Years
Megan Fox Quits Twitter After 6 Days: Who Else Quit (and Who Came Running Right Back)?
Kate Middleton's Portrait Unveiled, Looks a Little... Rough
From Our Partners:
25 Risqué Miley Cyrus Stage Outfits (Celebuzz)
Guess the Celebrity Bikini Body! (Celebuzz)


text:
Coach Skills Course
- Download 3 modules
- Join Live Teleclasses
- Access Community Forum
Become a Certified Coach
Established in 2001, International Coach Academy is a leading coach training school with thousands of students and graduates in over 90 countries.
Ready to get started with Coach Training? –> Expression of Interest
Wanting to Experience Coach Training? –> Join Coaching 101 (free course)
Researching Coach Training Schools? –> Talk to a Program Advisor
Not sure if Coaching is for you? –> Join a Coaching Group (free membership)
Meet Our Graduate Coaches
Visit Our Coaching Library
Coach Street Podcast
Join Robyn Logan and Andrea Lee on this great podcast about all things coaching.
Find out more.
Coaching Case Studies
Coaching Models, Power Tools, Research Papers. -all created by our students
Find out more.
Day in the Life
Video Interviews with Graduate Coaches with a diverse range of niches.
Find out more.
Coaching Tips
Get tips and strategies in our regular Coaching Tips Videos
Find out more.
Graduation Yearbooks
Regular publication showcasing our amazing graduates
Find out more.
Coaching 101 Minutes
A recap of the conversations and questions covered during our Coaching 101 Classes.
Find out more.


text:
A multiple-vehicle accident closed the Ohio Turnpike in both directions Thursday around 10:30 a.m. near milepost 32 in Fulton County. All lanes have been reopened.
According to the Ohio State Highway Patrol, John Adams, 62, of Kelseyville, CA, was driving a semi truck eastbound on the Ohio Turnpike when he lost control and drove off the left side of the roadway, crossing through the median and overturning. The semi truck continued in the westbound lanes, striking a semi truck driven by Joshua Shontz, 22, of Oil City, PA, and a Chevrolet HHR driven by Vance McCrumb, 70, of Milan, MI. The Ohio Turnpike accident/incident team said Shontz saw the accident happening but couldn't do anything to stop, so he jumped to the other side of his cab and ducked down.
SLIDESHOW: Accident closes turnpike west of Wauseon
After impact, Adams' and McCrumb's vehicles left the north side of the roadway and came to rest in the ditch. The trailers of Adams and Shontz remained on the roadway blocking the westbound lanes.
Adams' truck was hauling general freight. Shontz' truck was hauling lumber. Both spilled their loads onto the roadway. According to Toledo News Now's Nicole Collier, one truck was full of audio/visual equipment labeled "Swedish House Mafia, San Francisco, CA." They were making the trip from Chicago to their next venue in Toronto.
No hazmat crews were called to the scene because no fuel spilled.
The Jaws of Life were used to extricate Adams and McCrumb. Workers said it took a very long time to get out McCrumb. They were both taken to Toledo hospitals by air ambulance.
OSHP says Adams and McCrumb both have non-life-threatening injuries. Shontz was able to free himself without assistance and also has non-life-threatening injuries. According to OSHP, McCrumb and Shontz were wearing their seatbelts at the time of the crash. However, seatbelt use for Adams is unknown.
Traffic was at a standstill. According to OSHP dispatcher, eastbound and westbound lanes of the Turnpike closed between SR 108 and SR 66 after the crash. The accident happened near milepost 32, two miles west of Wauseon. All westbound traffic was diverted off of the Wauseon Interchange at exit 34. The westbound lanes of the Ohio Turnpike were closed for approximately three hours.
The crash remains under investigation.
Copyright 2013 Toledo News Now. All rights reserved.
1115 Mt. Auburn Road
Public File Contact:
FCC Public File
Local News
All content © Copyright 2000 - 2014 WorldNow and WFIE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.


text:
In the first epistle by his name, John has provided multiple ways for us to test our experience in Christ. We'll consider a few of these.
First there is the "light-dark" test. "God is light, and in him is no darkness at all. If we say that we have fellowship with him, and walk in darkness, we lie, and do not the truth: But if we walk in the light, as he is in the light, we have fellowship one with another, and the blood of Jesus Christ his Son cleanseth us from all sin" 1 John 1:5-7. Did you notice the wonderful promise that accompanies that test? Some would question how they can know if they're walking in light. Another test might illuminate the answer.


text:
William Warren Gruber, a retired local businessman, departed this life on June 16, 2011.
He was born in Detroit, Michigan on Oct. 4, 1941.
He leaves behind his wife, Sue Sanders Gruber, to cherish memories of 47 years of marriage. He is also survived by his brother, Douglas Gruber of Fort Wayne, Indiana.
According to his wishes, there will be no service at this time.


text:
Hello fellow sewing enthusiasts!! It's me, Melissa. I am so excited to be able to bring you another quilt tutorial here at the Moda Bake Shop. I absolutely fell in love with the Sugar Pop line by Liz Scott the second I saw it and was so happy to get to work with these amazing fabrics!
Do you love this quilt and the fabric as much as I do? Then click on over to Burgundy Buttons where Leah has created a Sugar Pop N Change Quilt Kit just for you!
Now onto your sashings :)


text:
Customer Reviews for Solids Sheer Window Shades
"Fantastic Find"
By Katie from Racine, Wisconsin
We have a huge bedroom window and were replacing UGLY mini blinds. We wanted something that provided a view during the day and privacy at night. These vertical shades/sheers were just what we wanted. In addition, they added a stunning appearance to our bedroom! Couldn't be happier.View this product
"10 feet Levolor sheers"
By venk from La Mesa, CA
Absolutely the best. Make sure you have at least 3 inches clearance behind where the headrail mounts screw into the window frame. Lovely quality. Levolor shipped me replacement sheers when one of the windows happened to be a mite shorter than my measurement. WOW!View this product


text:
The Megaminx originally entered production in 1982, but since its first limited-edition incarnation its popularity has risen. Recently, Uwe Meffert acquired the molds for the Megaminx and started production of what he says is the "most complicated Magic Polyhedron in production". The newer version, however, has tiles instead of stickers, a first for the Megaminx.
The Megaminx isn't much more difficult to solve than the Rubik's Cube, because although there are many more pieces (and many more combinations) the number of faces to turn allows you a great deal of freedom when much of the Megaminx is already solved.
DISCLAIMER: The following table contains user-generated content. This information is collected to serve as a rough guideline and is certainly not complete and may not even be accurate. This information is filtered and carefully moderated, but incorrect information will inevitably find its way into the system. Always use your own judgement when buying or selling an item.
Thank you to the following people for their assistance in helping collect the information on this page: qqwref, Mitch Bugaj. If you have any information or images that you would like to contribute to this entry, please click the apropriate add () or edit () icon above, or use the following links to modify this item, add a recent sale price or to add a new link.


text:
11 U.S. Code § 767 - Commodity broker liquidation and forward contract merchants, commodity brokers, stockbrokers, financial institutions, financial...swap participants, repo participants, and master netting agreement participants
prev | next
Notwithstanding any other provision of this title, the exercise of rights by a forward contract merchant, commodity broker, stockbroker, financial institution, financial participant, securities clearing agency, swap participant, repo participant, or master netting agreement participant under this title shall not affect the priority of any unsecured claim it may have after the exercise of such rights.
Source(Added Pub. L. 109–8, title IX, § 907(l),Apr. 20, 2005, 119 Stat. 181.)
Effective Date
Section effective 180 days after Apr. 20, 2005, and not applicable with respect to cases commenced under this title before such effective date, except as otherwise provided, see section 1501 ofPub. L. 109–8, set out as an Effective Date of 2005 Amendment note under section 101 of this title.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.
|Description of Change
|Session Year
|Public Law
|Statutes at Large
LII has no control over and does not endorse any external Internet site that contains links to or references LII.


text:
- {"imageName":"http://s7d2.scene7.com/is/image/TheCompanyStore/sheets_e1i6_A12?$dw280$"}
- {"imageName":"http://s7d2.scene7.com/is/image/TheCompanyStore/duvet_e1i6_A12_web?$dw280$"}
- {"imageName":"http://s7d2.scene7.com/is/image/TheCompanyStore/duvet_du32_k12_bg?$dw280$"}
- {"imageName":"http://s7d2.scene7.com/is/image/TheCompanyStore/sheets-e1i4-f13?$dw280$"}
Legends® Luxury 500-Thread Count Dot Sateen Bedding
Legends® Luxury 500-Thread Count Dot Sateen Flat Sheet
Please select Size & Color first then, check the TCS monogram box to view all monogramming options.
View All Styles{"title":"View All Styles","height":"450","width":"600px"} View All Fonts{title:"View All Fonts",height:"450",width:"600px"} View All Colors{title:"View All Colors",height:"450",width:"600px"}
**Monogram items are non-returnable due to their customization.
Legends® Luxury 500-Thread Count Dot Sateen Fitted Sheet
- 500-thread count woven dot sateen bedding.
- Bedding made of 500-thread count Supima® cotton – America's finest grown cotton.
- Generously sized flat and fitted sheets accommodate mattresses up to 17" deep.
- Machine wash.
- Imported.
- Exclusively ours.
- Personalize: Flat Sheet-Monogram is located on the fold back, 3 1/2" from the lower seam, Pillowcase-2 1/2" above the seam, Sham-Monogram is centered horizontally, Comforter Cover-33" inches down from closed end of duvet (centered)
Bask in five-star luxury with our exquisite Legends 500-thread count bedding. Made from long-staple Supima® cotton – the finest American-grown cotton – this bedding is spun with 500 super-fine threads to every square inch for unrivaled softness and durability. From sheets and pillowcases to duvet and comforter covers, you'll sleep like royalty every time you climb into a bed outfitted with our outstanding woven dot sateen bedding.


text:
Interview: Kyle Rankin - DNSSEC @ SCALE 12xSubmitted by Ilan Rabinovitch on Wed, 2014-02-05 22:25
Interview by Eric Van Johnson
Interview by Eric Van Johnson
Guest Post by Phil Dibowitz
We've received a lot questions about the PGP Keysigning Party this year, and I'm happy to report that it is indeed going to happen.
However, your faithful PGP enthusiast is taking a year off. Instead of me standing up and yelling instructions, Aaron Toponce has graciously volunteered to lead this year's event. Aaron has led many PGP keysigning parties and I'm sure he will bring his own unique insights and twist.
The SCALE team is pleased to announce that Leslie Hawthorn has been named as one of our keynote speakers for SCALE 12X, the 12th annual Southern California Linux Expo, in February.
Leslie will speak on "Why Checking Your Privilege is Good for *You*"
The SCALE team is pleased to announces that Brendan Gregg has been named the first of two keynote speakers for SCALE 12X, the 12th annual Southern California Linux Expo, in February.
Gregg will speak on "What Linux Can Learn from Solaris Performance, and Vice Versa."
SCaLE 12X – the 12th annual Southern California Linux Expo – takes place on Feb. 21-23, 2014, at the Hilton Los Angeles Airport hotel. As the first-of-the-year Linux/Open Source software expo in North America, SCaLE 12X expects to host more than 100 exhibitors this year, along with nearly 80 sessions, tutorials and special events
SCaLE is a community run open-source and free software conference held annually in Los Angeles.
Present! The SCALE Call For Papers is now closed!
Sponsor! Sponsorship and Non-Profit & dotORG exhibitor opportunities are available.
Attend! Registration for SCALE 12X opens on September 22, 2013.
Get Involved! Interested in helping to plan this year's conference? Get in touch!
The Southern California Linux Expo turned their annual event up to 11 this year in more ways than one.
SCALE 11X, celebrating its 11th year as the first-of-the-year Linux/Open Source expo in North America, played host to more than 2,300 attendees visiting more than 100 exhibitors and hearing more than 90 speakers giving a wide variety of presentations during the course of the three-day event.
SCALE 11X attendees voted on their favorite Saturday exhibitors in six different categories, and exhibitors went all out to impress.
The envelope, please . . .
The winners of the SCALE 11X Exhibitor Contest are:
Favorite Clothing Item: Puppet Labs
Most Interesting Swag: HP
Strangest Swag: Zenoss
Most Useful Swag: Silicon Mechanics
Most Passionate .Org: BeagleBoard/PandaBoard
Most Memorable Booth: LinuxChix
Honorable mentions go to: Fedora, RackSpace, O'Reilly Media, Linux Astronomy, OpenStack, M-Go, EFF, So Cal Python.
Jason Brooks took some time to talk to the Scale Team about his presentation, "oVirt: open your virtual data center". Jason is speaking on Saturday at 6PM in the La Jolla room.
Q: Could you please introduce yourself and tell us a little about your background?
The SCALE team wants to generate buzz about exhibitors and provide an icebreaking opportunity for vendors to reach out to attendees in the exhibit hall. So we have a new activity this year to help our attendees appreciate the presentation you've created at your booth, our new Exhibitor Contest.
Every badge sheet this year has a "Favorite SCALE Exhibitors" contest ballot printed on it, for attendees to slip into their badge sleeves. If you want to participate, this is your opportunity: you can ask attendees to vote for you on the spot, anytime, anywhere.
We had a chance to sit down with Guillermo Antonio Amaral Bastidas, SCALE 11x speaker and exhibitor, and discuss some of the exciting projects he's been working on. Guillermo will be speaking about his free & open source video game system, as well as showing it off in his exhibitor booth.
SCALE: Could you please introduce yourself and tell us a little about your background?


text:
Posts categorized "Winter Games Watch"
VIDEO: Takes From Tubbs- Tues. August 19, 2014by Chris Tubbs
Thoughts on the post SummerSlam RAW.Read More »
U.S. Olympian Kate Hansen Cries Wolf... For Reals.by Jeff Frieders
YouTube Description: Epic #SochiFail: Wolf in my hall - I'm pretty sure this is a wolf wandering my hall in Sochi. To be fair, h...Read More »
The Real Russia :: What It's Like at the Games - The Land Where Only Cash is Kingby Mary Kay Wright
The Land Where Only Cash is King! The first thing you learn pretty quickly about Russia is that you will be expected to pay ...Read More »
The Competition Is The Thingby Tom King
:04 a.m. by Tom King Read a great piece in on grantland.com yesterday by...Read More »
Curling Has It Rightby Nick Vitrano
I love the Olympics, but for some reason this go 'round hasn't captured my interest as prior games. I don't have an answer for it...Read More »
The Real Russia :: What it's Like at the Games - The Best Russian Souvenirs to Bring Backby Paul Heling
The best souvenirs to bring back from Russia (that are difficult to get anywhere else in the world) Hand painted lacquer boxes....Read More »
The Race for Funding :: What it Costs An Athlete to Compete in The Gamesby Paul Heling
What it Costs an Athlete to Compete It can vary, but a decade of training and equipment bills can cost six figures. A f...Read More »
The Real Russia :: What it's Like at the Games - Attack of the Russian Supermodelsby Mary Kay Wright
Attack of the Russian Supermodels There is a common stereotype that Russian women are very beautiful – unfortunately for us...Read More »


text:
Forgive the repeat from February while I check my collection for some more organic or biodynamic producers.
Picked up this wine and the BV Coastal Estates Sauvignon Blanc at the grocery store after they were listed among the best value wines for 2008 in "Wine Enthusiast." This one found more favor with me than the BV Sauvignon Blanc.
13.8% alcohol by volume, made from organic grapes, barrel aged in French and American oak. Retails for about $11-$13.
Medium straw color. Some oak on the nose along with green apple. Crisp apple/pear flavors in the mouth. Good acids--balanced. Crisp, tasty and food-friendly. I had it over several nights with chicken in white-wine sauce and saffron rice. I would consider purchasing again for a midweek wine.


text:
Home » Knuckles Madsen » News
Knuckles Madsen
Real Name
Kevin Nickel
Date of Birth
November 30, -0001
Place of Birth
Back in December, WWE opted to release Knuckles Madsen from his developmental contract. He never came close to being called up to the main roster. Madsen must feel that the door on a return has been closed, as he has decided to unleash his bitterness towards the company. He has been taking jabs at Billy Gunn and Bill DeMott online.
February 19, 2014
Earlier today, WWE informed Knuckles Madsen that he has been released from his contract. The developmental wrestler has been with the company since 2012. Prior to that, he was working with OVW, where he may try to return to now.
December 17, 2013
It appears that Knuckles Madsen has been pretty much blacklisted by the big companies in professional wrestling. The former developmental wrestler was pretty bitter towards WWE after they released him. TNA and ROH have not expressed much interest in signing him to a contract. There have also been no rumors about him joining Jeff Jarrett in Global Force Wrestling, even though every available wrestler has been rumored to sign with the new promotion.
April 28, 2014
"There are quite a few trainers and classes. There are a lot of vultures flying around there who will take the move if they like it so I was careful. I just worked with the great trainers. At the performance center, there is a man there who is just great. Norman Smiley, he is a surgeon in the ring. It was incredible. I would love to say I could do The Big Wiggle so I am going to yeah, I can do the wiggle."
January 18, 2014
For MMA fighters, you only have a certain amount of time in the business, so you want to get as many fights as humanly possible before you retire. Bobby Lashley is fully aware of this theory, and he embraces it. The TNA star won a fight earlier this month for Bellator, and he's already scheduled for another one next month at a show in Kansas.
September 22, 2014
Professional wrestling came close to losing another beloved performer this week. While working at an independent wrestling show outside of Omaha, Nebraska, Bobby Eaton started having seizure like effects. It got bad enough to where he was rushed to the hospital. Doctors believe that he suffered a heart attack, and his defibulator and pacemaker prevented him from dying.
September 22, 2014
Michael Moody has passed away. While he's not necessarily a well known name in the world of professional wrestling, many will remember him as being the son of the legendary Paul Bearer. When the company wanted to induct the iconic manager into their hall of fame, WWE enlisted the help of his two sons to do the honors. Moody was 34 years of age and passed away in his sleep.
September 22, 2014
Knowing the right people is still an asset in the professional wrestling industry. During a recent interview, Matt Hardy revealed that there have been ongoing negotiations between TNA and his wife, Reby Sky. She worked a one night only pay per view for the company, and there was mutual interest back then. With Hardy back in TNA, her chances of being signed have improved tremendously.
September 21, 2014
TNA could be losing another big name performer, as their contract with Kurt Angle is expiring at the end of the day. He already told fans that an official announcement on his future will be made soon. The former world heavyweight champion has long stated that he has a desire to do one more run with WWE before retirement. With the company desperately lacking top level performers, a reunion is quite possible.
September 21, 2014
Some good news if you're a fan of Ric Flair. He has now been released from a hospital in Georgia after spending ten days there for emergency surgeries. The former world heavyweight champion had an appendicitis attack and a hernia. He is expected to take some time off the road to recover from his wounds, but he should be back on WWE television before the end of the year.
September 20, 2014
Some really awful news for WWE this weekend, as Roman Reigns had to be rushed to the hospital. The rising star is undergoing surgery for an incarcerated hernia. Reigns will be forced to miss his Night of Champions 2014 match against Seth Rollins. Since the match was a featured one, the pay per view has suffered a bit of a blow. No word yet on what WWE intends to do with that slot.
September 20, 2014
When the decision was made between TNA and Spike to move Impact Wrestling to Wednesday nights instead of Thursday, both sides were aware that it might take some fans time to get used to that. As expected, the ratings dropped initially. However, Dixie Carter and company have been slowly turning things around, and a lot of the viewers are now aware that they are on a different day.
September 19, 2014
Not a lot of details were provided when Ric Flair was forced to miss a WWE NXT show to have surgery. Jim Ross has revealed some details on that procedure. The longtime commentator stated that Flair had an appendicitis attack, and when doctors went in there to repair the damage, they discovered a hernia, so they repaired that as well. No word yet on when Flair will be returning to WWE television.
September 18, 2014
Since he abruptly retired from professional wrestling, Charlie Haas has been relatively quiet. He abandoned his Twitter account, and he only appeared sporadically at obscure independent wrestling shows in Texas. The former WWE star is making a little comeback in November, though. He will be teaming up with Shelton Benjamin for a Jersey All Pro show in Rahway, New Jersey.
September 18, 2014
Earlier this month, it was revealed that WWE pays their developmental wrestlers approximately $25,000 a year. It has now been discovered that the amount is only for the male performers. The divas in WWE NXT, such as Ashley Flair, Bayley and Sasha Banks, are paid $50,000 a year, which is twice as much. The reasoning behind that is because management feels that the girls have more expenses in maintaining their looks.
September 18, 2014
Big Time Wrestling has come up with a big time promotional idea. The company has signed on Ric Flair and Ricky Steamboat to make appearances together at two shows in November. The first event will be in Springfield, Massachusetts, while the other will be in Fishkill, New York. This will be the first time in a very long time that the two of them have made an appearance together.
September 18, 2014
As many already know, Rob Van Dam is taking some time off from WWE. However, that does not mean that he is taking time off from professional wrestling. The former world heavyweight champion is working an independent wrestling show in Florida later on this month. Due to his name value and recent stint with WWE, RVD is able to command a higher pay than the typical performer at these shows.
September 17, 2014
During a recent interview, Evan Bourne was asked about his time in WWE. The high flying performer revealed that he had a good amount of fun during his stint with the company. However, he stated that management fired him via fax instead of a more personal phone call. No word yet on whether or not that is the new policy for WWE, but in the past, phone calls were made to the performers being given a release.
September 17, 2014
The downplaying of the Great Khali continues. WWE is doing some promotional work in India this week, and once again, the former world heavyweight champion was not chosen for the task of generating interest in his own country. Instead, WWE has sent Wade Barrett, a European star who is currently injured. The belief is that management will be severing ties with Khali once his contract expires because he is one of higher paid performers on the roster.
September 17, 2014
During a recent interview, Jim Ross revealed just how close Brock Lesnar and Shelton Benjamin were in college. Ross was the one that recruited Lesnar into WWE, and when a contract was offered, Lesnar stated that he had a special stipulation he would like fulfilled. Lesnar told the company that he would sign the contract if they also gave a deal to Benjamin, who happened to be his roommate at the time.
September 16, 2014
In a bit of news that is sure to cause mass speculations about Vince McMahon and company, it has now been announced that there will be a delay in the launch of WWE 2K15. The video game was initially scheduled to be released in North America on October 28. It has ow been pushed back to November 18. The official word given for the move is because both companies wanted to produce the best possible game before releasing it to the fans, but as many already know, that is simply public relations talk.
September 16, 2014
During a recent interview, Dixie Carter was asked about the situation involving the departure of AJ Styles from TNA. She stated that she felt the company gave him a respectful offer. While she did praise him as a model employee, Carter also goes on to state that she feels that Styles made a mistake by not accepting the contract. The former world heavyweight champion has publicly stated that he felt that the offer was insulting.
September 16, 2014
If you're a big fan of Chris Jericho, then definitely check out Night of Champions 2014, as that will be the last time that we see him in WWE for quite some time. The former undisputed heavyweight champion will be working a match against Randy Orton. He finishes up with the company shortly afterwards. Jericho has a tour with Fozzy coming soon, and he will be traveling around to promote his new book.
September 15, 2014
Since he has a history of partying and the company does not want rumors to run wild with internet fans, WWE has released an official statement in regards to why Ric Flair was recently forced to miss some live events. They stated that he was hospitalized and will be back with the company soon. WWE had issues with the former world heavyweight champion at a public event involving their upcoming WWE 2K15 video game a while back.
September 15, 2014


text:
to McCombs
Home ·
Texas MSTC ·
Program Information ·
Corporate Job Positions
To learn more about hiring our students for internships or full-time employment, please check our career page.
The Master of Science in Technology Commercialization (MSTC) Program prepares graduates to launch technology innovations successfully into the marketplace. It includes ten highly integrated courses progressing from the early stages of new technology assessment and development through the launch of new products or ventures.
MSTC graduates have the knowledge, skills, and abilities to:
• Estimate the market potential of new technologies
• Specify which attributes and benefits of a new technology should be included in new products
• Write and present the case for funding high potential technologies
• Develop a plan for launching new, technology-based products into the market.
As a result, MSTC graduates operate in both the technology commercialization space and related areas that rely on these skills and abilities. Some corporations have technology commercialization departments and others use different descriptions for these functions. Job titles of previous graduates are listed in four major categories below. Our students have a broad range of work experience, so students will be seeking employment at all levels of the organization.
Page last updated: 5/15/2013
By phone: (512) 471-5921
By mail:
1 University Station, B6000
Austin, TX 78712-1178
In person:
2110 Speedway
Austin, TX 78705
©2014 McCombs School of Business, The University of Texas at Austin | Technology Resources | Contact Us


text:
Don, my heart breaks with yours because I know you suffer along with Carol for every pain and problem she has. Both of you are in my prayers.
Allison, I hope you have a lovely, painfree time at Urbana, and that your surgery goes well.
Laurie, I, too, am glad you had a good Christmas Day.
We enjoyed our family at Christmas time. They're our special blessings.
Carole, I hope all your travels are safe.
Edy, I pray you and husband get over your illnesses quickly. It seems so many right now are covered with colds and flus and other viruses.
Mariane, Dear, I hope your pains are not keeping you from the joy of your precious boys.
Wishing a double portion of God's blessings to all on the porch.


text:
Featured Events
- Amy Schumer
- Anjelah Johnson
- Atlantic City Comedy Fest
- Aziz Ansari
- Bill Burr
- Bill Cosby
- Bill Maher
- Brian Regan
- Cedric the Entertainer
- Chris D'Elia
- Comics Come Home
- Craig Ferguson
- Daniel Tosh
- Dave Chappelle
- Frank Caliendo
- Gabriel Iglesias
- George Lopez
- Jackie Mason
- Jay Leno
- Jeff Dunham
- Jerry Seinfeld
- Jim Gaffigan
- Jim Jefferies
- Joe Rogan
- John Oliver
- Kevin James
- Larry the Cable Guy
- Last Comic Standing
- Lewis Black
- Mark Twain Prize for American Humor
- Mike Birbiglia
- Mike Epps
- New York Comedy Festival
- Nick Swardson
- Penn and Teller
- Rodney Carrington
- Ron White
- Russell Peters
- Seth Meyers
- Terry Fator
- Tim Allen
- Wanda Sykes
- Whose Live Anyway?
We're sorry, but we currently have no tickets available for this event.
Check out our full selection of Comedy tickets or sign up to be notified when tickets for this event are available.
Gene Simmons Roast Ticketing Information
Vivid Seats is a leading source for Gene Simmons Roast tickets. Vivid Seats not only offers cheap Gene Simmons Roast tickets, but Vivid Seats also offers venue-seating charts which gives you the power to choose your own seats. After you browse Gene Simmons Roast show dates and choose where you want to sit, enter your payment information into our secure server. With Vivid Seats your privacy is 100% guaranteed along with your authentic and exact Gene Simmons Roast tickets. Your comedy show tickets will arrive on time. If you cannot make the show, you may try to sell your Gene Simmons Roast tickets back through our site. If you have questions regarding upcoming comedy tickets or if you would like more ticketing information, please call us at: 866-848-TIXX.


text:
The Midwest was recently hit with a small hailstorm. Auto dealerships, auto body and roof repair businesses are all over the air looking for your patronage.
But, according to Wikipedia, the hail we just had pales in comparison to some of the biggest, baddest, hailstorms on the planet.
On April 14th 1999, Sydney, Australia was hit with that country's most expensive storm. Hail damaged more than 20,000 properties, 40,000 vehicles and 25 aircraft. Costs were estimated at $3.3-billion.
Chicago was struck with softball-sized hail that reached up to three-feet deep in places on May 18th 2000, causing $572-million in damage.
Closer to home, Vivian, SD is home to the world's largest hail stone on record. It was bigger than a bowling ball. Checking in with an 8-inch diameter and weighing nearly two-pounds. This beast fell from the sky on July 23rd 2010.
As you deal with the aftermath of this latest storm, know that it could always be worse.
*images courtesy of: Pixabay.com


text:
- << Previous photo
- Next photo >>
Shop Our Store
More Ways To Shop
More Ways To Save
Select your preferred location and we'll note which parts are ready to be picked up TODAY.
Spark Plug, E3, Gasket Seat, 14mm Thread, .750 in. Reach, Projected Tip, Resistor, Each
Estimated Ship Date: Today Would you rather pick it up? Select Location
View Similar Products
E3 Spark Plugs are the product of years of fundamental research in the combustion field. The unique patented electrode configuration of these new E3 spark plugs increases the amount of combustion pressure created during each power stroke of an engine, which results in a marked increase in power output, fuel economy, and reduced emissions in all gasoline engines.
Some parts are not legal for sale or use in California on any pollution-controlled motor vehiclesBack To Results